Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 50

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 50
---

of our employees to be an important driver of our business and key to our future prospects. We monitor our compensation programs closely
and provide what we consider to be a very competitive mix of compensation and insurance benefits for all our employees, as well as participation
in our equity programs. None of our employees is subject to a collective bargaining agreement or represented by a trade or labor union.
We consider our relations with our employees to be good.

Corporate Information

We were incorporated under
the laws of the State of Nevada on September 25, 2015. Our principal executive office is located at 225 NE Mizner Blvd, Suite 640, Boca
Raton FL 33432 and our telephone number is (858) 964-3720.

Item 1a. Risk Factors

Summary of Risk Factors

Below is a summary of the
principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that
we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under
the heading “Risk Factors” and should be carefully considered, together with other information in this Form 10-K and our other
filings with the SEC, before making an investment decision regarding our common stock.

    ●
    We will require additional capital to finance our operations to continue as a going concern, which may not be available to us on acceptable terms, if at all. As a result, we may not complete the development and commercialization of our product candidates or develop new product candidates and have substantial doubt about our ability to continue as a going concern.

    ●
    Our ability to successfully engage with, and satisfactorily respond to, requests for information from the FDA in the future.

    ●
    We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future.  We are not currently profitable, and we may never achieve or sustain profitability.

    ●
    We will require additional capital to fund our operations and if we fail to obtain necessary financing, we will not be able to complete the development and commercialization of our product candidates.

    ●
    We are significantly dependent on the success of our DN-TNF product platform and Natural Killer Cell Priming Platform (INKmune), CORDStrom, and our product candidates based on these platforms.

    ●
    We need to attract and retain highly skilled personnel; we may be unable to effectively manage growth